Abstract: The disclosure provides a process for the preparation of 3-(4?-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof, contemplated to be capable of modulating the activity of receptors, e.g., PPARs receptors.
Type:
Grant
Filed:
February 10, 2020
Date of Patent:
February 20, 2024
Assignee:
Nogra Pharma Limited
Inventors:
Salvatore Demartis, Francesca Viti, Marie McNulty
Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
September 12, 2023
Assignee:
Nogra Pharma Limited
Inventors:
Sergio Baroni, Salvatore Bellinvia, Francesca Viti
Abstract: The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-? in a subject.
Abstract: The present invention relates to methods of treating, preventing or managing intestinal fibrosis by inhibiting SMAD7. The invention is also directed to methods of monitoring effectiveness of treatment or management of intestinal fibrosis using a SMAD7 antisense oligonucleotide, as well as methods of regulating SMAD7 antisense oligonucleotide treatment, based on analysis of Transforming Growth Factor-? (TGF-?) levels, ?-Smooth Muscle Actin (a-SMA) levels, and/or phosphorylated Mothers Against Decapentaplegic Homolog 3 (p-SMAD3) levels.
Abstract: The present invention relates to methods of treating, preventing, and/or managing celiac disease by inhibiting SMAD7. The invention is also directed to methods of monitoring effectiveness of treatment or management of celiac disease using a SMAD7 antisense oligonucleotide, as well as methods of regulating SMAD7 antisense oligonucleotide treatment, based on analysis of Transforming Growth Factor-? (TGF-?) signaling activity.
Abstract: The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound.
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
June 29, 2021
Assignee:
Nogra Pharma Limited
Inventors:
Sergio Baroni, Salvatore Bellinvia, Francesca Viti
Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.
Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.
Abstract: The present disclosure is directed in part to heterocycles, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
February 18, 2020
Assignee:
Nogra Pharma Limited
Inventors:
Daan Hommes, Auke Verhaar, Gijs Van den Brink, Francesca Viti
Abstract: Methods of treating a subject with IBD with an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CRP levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CRP levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CRP levels may correlated with IBD remission or decreases in CDAI score. The present invention also relates to treatment of IBD using an anti-SMAD7 therapy (e.g., an antisense oligonucleotide) in combination with an additional agent. The invention also features related pharmaceutical compositions and kits.
Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.
Type:
Grant
Filed:
August 10, 2018
Date of Patent:
October 15, 2019
Assignees:
Nogra Pharma Limited, University of Miami
Inventors:
Giovanni Monteleone, Peter Buchwald, Luca Inverardi, Antonello Pileggi, Camillo Ricordi, Alice Tomei
Abstract: The present invention relates to treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) using antisense nucleotides that are directed against polymorphic forms (e.g., those containing single nucleotide polymorphisms) of the SMAD7 mRNA. The invention thus relates to treatment methods for subjects having polymorphic forms of SMAD7 and antisense oligonucleotides that specifically target SMAD7 mRNA transcripts containing polymorphisms.
Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.
Type:
Grant
Filed:
October 26, 2016
Date of Patent:
April 30, 2019
Assignee:
Nogra Pharma Limited
Inventors:
Sergio Baroni, Salvatore Bellinvia, Francesca Viti
Abstract: The present disclosure is directed in part to heterocycles, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses.
Type:
Grant
Filed:
May 31, 2013
Date of Patent:
February 19, 2019
Assignee:
Nogra Pharma Limited
Inventors:
Daan Hommes, Auke Verhaar, Gijs Van den Brink, Francesca Viti
Abstract: Disclosed herein are antisense oligonucleotide sequences against IL-34 and methods for treating inflammatory diseases, such as inflammatory bowel disease, and/or fibrosis, associated with elevated activity or expression of IL-34. Also disclosed are pharmaceutical compositions containing an IL-34 antisense oligonucleotide useful for treating inflammatory diseases and/or fibrosis and manufacture of medicaments containing a disclosed IL-34 antisense oligonucleotide to be used in treating inflammatory diseases and/or fibrosis.
Type:
Application
Filed:
November 25, 2016
Publication date:
November 29, 2018
Applicant:
Nogra Pharma Limited
Inventors:
Marie McNulty, Francesca Viti, Salvatore Bellinvia
Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.
Type:
Grant
Filed:
April 18, 2013
Date of Patent:
September 25, 2018
Assignees:
University of Miami, Nogra Pharma Limited
Inventors:
Giovanni Monteleone, Peter Buchwald, Luca Inverardi, Antonello Pileggi, Camillo Ricordi, Alice Tomei